WenTongGanPi decoction alleviates diarrhea-predominant irritable bowel syndrome by improving intestinal barrier

被引:2
|
作者
Li, Yaoguang [1 ]
Chen, Yangyang [2 ]
Liao, Zhengyue [3 ]
Liu, Yixin [3 ]
Liu, Chenhao [4 ]
Yang, Wenjing [3 ]
Bai, Jing [3 ]
Huang, Xinggui [4 ]
Hao, Yule [4 ]
Liu, Sijing [1 ,3 ]
Liu, Yi [1 ]
机构
[1] Chengdu Univ Tradit Chinese Med, Coll Clin Med, Chengdu 611103, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Coll Pharm, Chengdu 611103, Peoples R China
[3] Chengdu Univ Tradit Chinese Med, Coll Med Technol, Chengdu 611103, Peoples R China
[4] Chengdu Univ Tradit Chinese Med, Coll Basic Med Sci, Chengdu 610075, Peoples R China
关键词
WenTongGanPi decoction; Irritable bowel syndrome; Diarrhea; MAPK signal pathway; Intestinal barrier; Gut microbiota; CHAIN FATTY-ACIDS; Q-TOF-MS/MS; METABOLITE; MICROBIOTA; MAPK;
D O I
10.1016/j.jep.2024.118544
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: WenTongGanPi Decoction (WTGPD) is a representative medical practice of the Fuyang School of Traditional Chinese Medicine (TCM), which originated from the classical Lu's Guizhi method. WTGPD places emphasis on the balance and functionality of yang qi, and is effective in treating TCM symptoms related to liver qi stagnation and spleen yang deficiency. In TCM, diarrhea-predominant irritable bowel syndrome (IBS-D) is often diagnosed as liver depression and spleen deficiency, and the use of WTGPD has shown significant therapeutic effect. However, the underlying mechanism of WTGPD treating IBS-D remains unclear. Aim of the study: To explore the effect and mechanism of WTGPD in the treatment of IBS-D. Materials and methods: An IBS-D model with liver depression and spleen deficiency was constructed by chronic immobilization stress stimulation and sennae folium aqueous gavage. The impact of WTGPD on IBS-D rats was evaluated through measurements of body weight, fecal water content, and abdominal withdrawal reflex (AWR). Intestinal permeability was assessed using hematoxylin-eosin (HE), alcian blue-periodic acid schiff (AB-PAS), immunofluorescence (IF) staining, and quantitative real-time PCR (qRT-PCR). The components of WTGPD were analyzed using UPLC-Q-TOF-MS. The underlying mechanisms were investigated through network pharmacology, transcriptomics sequencing, western blot (WB), molecular docking, and 16S rRNA sequencing. Results: WTGPD treatment effectively alleviated diarrhea and abnormal pain in IBS-D rats (P P < 0.05). It enhanced the intestinal barrier function by improving colonic structure and increasing the expression of tight junction proteins (P P < 0.05). A total of 155 components were identified in WTGPD. Both network pharmacology and transcriptomics sequencing analysis highlighted MAPK as the key signaling pathway in WTGPD's anti-IBS-D effect. The WB results showed a significant decrease in p-p38, p-ERK and p-JNK expression after WTGPD treatment (P P < 0.0001). Guanosine, adenosine and hesperetin in WTGPD may be involved in regulating the phosphorylation of p38, ERK and JNK. Additionally, WTGPD significantly enhanced microbial diversity and increased the production of colonic valeric acid in IBS-D rats (P P < 0.01). Conclusion: In conclusion, our findings suggest that WTGPD can effectively alleviate IBS-D and improve intestinal barrier likely via inhibiting MAPK signal pathway and improving micobial dysbiosis.
引用
收藏
页数:15
相关论文
共 50 条
  • [1] The intestinal microbiome of diarrhea-predominant irritable bowel syndrome
    Carroll, I. M.
    Ringel-Kulka, T.
    Siddle, J. P.
    Ringel, Y.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2011, 23 : 13 - 13
  • [2] Ultrastructure of intestinal mucosa in diarrhea-predominant irritable bowel syndrome
    Zhao, D-Y
    Qi, Q-Q
    Long, X.
    Li, X.
    Chen, F-X
    Yu, Y-B
    Zuo, X-L
    PHYSIOLOGY INTERNATIONAL, 2019, 106 (03) : 225 - 235
  • [3] COLONIC IMPAIRMENT OF INTESTINAL BARRIER INTEGRITY CORRELATES WITH SYMPTOMS IN DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME PATIENTS
    Cocca, S.
    Gori, M.
    Altomare, A.
    Emerenziani, S.
    Cicala, M.
    Guarino, M.
    DIGESTIVE AND LIVER DISEASE, 2018, 50 (02) : E74 - E75
  • [4] COLONIC IMPAIRMENT OF INTESTINAL BARRIER INTEGRITY CORRELATES WITH SYMPTOMS IN DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME PATIENTS
    Cocca, Silvia
    Gori, Manuele
    Altomare, Annamaria
    Emerenziani, Sara
    Cicala, Michele
    Guarino, Michele Pier Luca
    GASTROENTEROLOGY, 2018, 154 (06) : S500 - S500
  • [5] Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome
    Lacy, Brian E.
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2016, 9 : 7 - 17
  • [6] Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome
    Kane, John S.
    Ford, Alexander C.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2016, 10 (04) : 431 - 442
  • [7] Role of Diet in Diarrhea-predominant Irritable Bowel Syndrome
    Singh, Prashant
    Nee, Judy
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2021, 55 (01) : 25 - 29
  • [8] Targeted therapies for diarrhea-predominant irritable bowel syndrome
    Olden, Kevin W.
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2012, 5 : 69 - 100
  • [9] Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome
    Ozdener, Ayse Elif
    Rivkin, Anastasia
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 2827 - 2840
  • [10] Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes
    Bleser, Scott
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (03) : 503 - 512